Drug General Information
Drug ID	D0E6SX
Former ID	DIB001038
Drug Name	AZD-5069
Synonyms	CXCR2 inhibitor (COPD), Astrazeneca
Indication	Chronic obstructive pulmonary disease [ICD9: 490-492, 494-496; ICD10:J40-J44, J47]		Discontinued in Phase 1	[548946]
Company	AstraZeneca plc
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	High affinity interleukin-8 receptor B	Target Info	Inhibitor	[533162]
KEGG Pathway	Cytokine-cytokine receptor interaction
	Chemokine signaling pathway
	Endocytosis
	Epithelial cell signaling in Helicobacter pylori infection
NetPath Pathway	TNFalpha Signaling Pathway
PANTHER Pathway	Inflammation mediated by chemokine and cytokine signaling pathway
	Interleukin signaling pathway
Pathway Interaction Database	IL8- and CXCR2-mediated signaling events
Reactome	Chemokine receptors bind chemokines
	G alpha (i) signalling events
WikiPathways	GPCRs, Class A Rhodopsin-like
	Peptide GPCRs
	GPCR ligand binding
	GPCR downstream signaling
	GPCRs, Other
References
Ref 548946	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030696)
Ref 533162	Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist. J Pharmacol Exp Ther. 2015 May;353(2):340-50.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.